Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Momelotinib (myelofibrosis) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-139
Last updated

Report documents

  1. Extract of dossier assessment

    Momelotinib (myelofibrosis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 303 kB, DE, PDF
    Download file : Extract of dossier assessment (PDF-Dokument, 303 kB, DE, PDF)

  2. Dossier assessment

    Momelotinib (myelofibrosis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 967 kB, DE, PDF
    DOI-Link
    https://doi.org/10.60584/A25-139
    Download file : Dossier assessment (PDF-Dokument, 967 kB, DE, PDF)

Drug assessment at a glance

  1. Drug assessment at a glance

    Momelotinib (myelofibrosis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 297 kB, EN, PDF
    Download file : Drug assessment at a glance (PDF-Dokument, 297 kB, EN, PDF)

Dossier assessment

Indication:

The treatment of disease-related splenomegaly or symptoms in adults with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis

Result of dossier assessment:
  • Patients who are JAK inhibitor naïve: added benefit not proven
  • Patients who have been treated with ruxolitinib: added benefit not proven

Project details

Project no.
A25-139
Commission
Commission awarded on 04.11.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI
https://doi.org/10.60584/A25-139

Connected Projects

  1. Dossier assessment

    Momelotinib (myelofibrosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V

    Project no.
    G24-04
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page